The study, appearing in the prestigious journal JAMA Network Open, outlines how OTX-202—a targeted digital therapeutic application designed explicitly to deliver suicide-specific cognitive and behavioral therapy—achieved a staggering 58.3% reduction in the recurrence of suicide attempts following hospital discharge. This finding is particularly noteworthy given that individuals who have previously attempted suicide represent a subset of patients most susceptible to repeated and potentially fatal suicidal actions. Conventional interventions have struggled to maintain long-term efficacy in this population due to accessibility barriers and the complexity of delivering tailored psychotherapy in real-world settings.

Clinically, the intervention’s efficacy extended beyond reducing suicide attempts; patients engaging with OTX-202 also exhibited sustained decreases in suicidal ideation that persisted for up to 24 weeks post-hospitalization. In contrast, participants assigned to an active control app—which provided safety planning and psychoeducational content—initially showed declines in suicidal thoughts that regrettably rebounded to baseline by the 24-week mark. These divergent trajectories underscore the value of specialized, therapeutic content over more general mental health resources in preserving gains during this critical period.

The researchers designed the trial as a multi-site, double-blind randomized controlled study encompassing 339 psychiatric inpatients recruited from six diverse hospitals across the United States. Participants were randomly assigned to receive either the OTX-202 app or an active control application, both adjunctive to treatment as usual. Importantly, the OTX-202 app delivered suicide-specific therapeutic modules grounded in evidence-based cognitive behavioral strategies, whereas the control app focused primarily on safety planning and psychoeducation without direct therapeutic engagement.

One of the key clinical outcome measures utilized was the Clinical Global Impression for Severity of Suicide-Change (CGI-SSC) scale, a clinician-rated instrument widely acknowledged for capturing symptom severity and improvement over time with high reliability across diverse patient populations and settings. Patients using OTX-202 demonstrated significantly greater clinical improvement as per this scale compared to controls, reflecting both symptom mitigation and increased potential for recovery.

The implications of this research are profound in light of the epidemiology of suicide in the United States, where suicide has ascended to become one of the top ten causes of death overall. It ranks second as a cause of mortality among individuals aged 10 to 14 and 25 to 34, third among those 15 to 24, and fourth among adults aged 35 to 44. The alarming upward trend—over a 33% increase in suicide rates since 1999—highlights an escalating public health crisis that demands innovative, scalable interventions capable of reaching patients where traditional services often falter.

Moreover, the economic burden of suicide and suicide attempts is staggering, with estimates indicating that these outcomes cost the U.S. healthcare system and the broader economy approximately half a trillion dollars every year. Despite this, suicide prevention remains uniquely underserved by pharmacologic or widely disseminated prescription products aimed at mitigating risk during high-risk periods post-hospitalization. OTX-202 thus emerges as a promising solution, leveraging mobile technology to provide accessible, cost-effective suicide-specific care at scale.

One of the enduring challenges in suicide prevention has been the scarcity of clinicians trained to provide specialized suicide-specific therapy in outpatient and community settings, particularly during the weeks and months immediately following hospital discharge—a timeframe recognized as the highest risk for completed suicide. Patients frequently face lengthy delays before accessing outpatient care, compounding their vulnerability during this critical interval. OTX-202 attempts to bridge this treatment gap by delivering evidence-based therapeutic content directly via patients’ smartphones, providing continuous support outside traditional clinical environments.

The development of OTX-202 was spearheaded by Oui Therapeutics, a digital therapeutics company dedicated to creating clinically validated mobile interventions for psychiatric populations. Their collaboration with academic investigators at Yale and Ohio State facilitated the rigorous validation of OTX-202’s clinical efficacy through this multisite trial. Such partnerships between industry and academia are crucial for accelerating the translation of digital therapeutics from innovation to real-world impact.

Senior author Dr. Seth Feuerstein, MD, JD, assistant clinical professor of psychiatry at Yale, emphasizes the unparalleled potential of this digital therapeutic: “Patients and those who care for them do not have access to reliable and effective tools and resources to reduce future suicide risk. This population faces arguably the biggest gap in access to effective interventions of any leading killer. The potential clinical and population health impact of this new option is extraordinary.” This sentiment echoes the urgent need for technological solutions that act as adjuncts or alternatives to traditional mental health care.

The study authors caution that while these results are promising, continued research and validation in broader, more diverse populations will be vital to confirm efficacy and inform best practices for integrating digital therapeutics into comprehensive suicide prevention frameworks. Furthermore, while OTX-202 offers scalable mental health support, it is intended to supplement—not replace—high-quality psychiatric care and ongoing clinical monitoring.

The collaborative nature of this study, involving clinicians and researchers from multiple institutions, strengthens the generalizability and rigor of the findings. Yale contributors include Patricia Simon, PhD; Samuel T. Wilkinson, MD; Lauren Astorino, MSN, APRN; Alecia D. Dager, PhD; and Seth Feuerstein, MD, JD, while Ohio State authors include Craig Bryan, PsyD; Kristen M. Carpenter, PhD; Luke Misquitta, MD; Katherine Brownlowe, MD; Lauren R. Khazem, PhD; Jarred Hay; and Austin G. Starkey.

Funding for the study was provided in part by Oui Therapeutics Inc and supported by a grant from the National Institute of Mental Health (R42MH123357). The researchers assert that the content reflects their scientific findings independently and does not represent official NIH positions.

This pioneering research heralds a transformative moment in suicide prevention, demonstrating that digital therapeutic interventions can effectively combat one of the most challenging and devastating public health problems of our time. With technology-enabled solutions like OTX-202, the future of mental health care may become more accessible, personalized, and responsive to the acute needs of vulnerable populations.

Subject of Research: Suicide prevention through digital therapeutic intervention among high-risk psychiatric inpatients.

Article Title: A Digital Therapeutic Intervention for Inpatients With Elevated Suicide Risk.

News Publication Date: August 8, 2025.

Web References:
JAMA Network Open Article
DOI: 10.1001/jamanetworkopen.2025.25809
Oui Therapeutics

References: [Study funded by NIMH Grant R42MH123357; Full article available in JAMA Network Open]

Keywords: Digital therapeutics, suicide prevention, psychiatric inpatients, mobile health, cognitive behavioral therapy, suicide-specific therapy, mental health technology, randomized controlled trial, post-discharge suicide risk, clinical global impression, behavioral health intervention, scalable mental health solutions.

The study, published in JAMA Network Open in August 2025, employed a rigorous, multi-site, double-blind randomized controlled trial involving 339 psychiatric inpatients from six diverse U.S. hospitals. Participants were randomly assigned to receive either the OTX-202 app or a control app, both in addition to their standard clinical care. Unlike the control app, which focused on safety planning and psychoeducation, OTX-202 delivered evidence-based suicide-specific therapy modules designed to sustain therapeutic gains beyond the hospital setting.

Remarkably, the trial revealed that among patients who had attempted suicide prior to hospitalization, use of OTX-202 reduced the rate of subsequent suicide attempts by an impressive 58.3%. This drop represents a critical breakthrough in the field, especially as post-discharge periods typically see high rates of suicide attempt recurrence. By targeting this vulnerable window, OTX-202 addresses a dire need for scalable and accessible interventions that can extend the reach of specialized therapeutic support.

Beyond reducing suicide attempts, patients using the OTX-202 app also experienced sustained reductions in suicidal ideation for up to 24 weeks after discharge. In stark contrast, those who engaged with the control app initially demonstrated some improvement in suicidal thoughts but saw those gains dissipate by the 24-week mark. This divergence highlights the app’s potential to preserve long-term mental health improvements when traditional therapy access is limited.

OTX-202’s development by Oui Therapeutics aims to fill a glaring void in mental health treatment infrastructure. Suicide-specific therapy, while well-established as an effective approach, faces barriers due to limited therapist availability post-hospitalization. The app offers a standardized and continuously available digital solution capable of delivering intervention with high fidelity and consistency across diverse patient populations and healthcare settings.

The study utilized the Clinical Global Impression for Severity of Suicide-Change (CGI-SSC) scale to objectively measure symptom severity and treatment response over time. Patients using the OTX-202 app showed statistically significant improvements on this clinician-rated scale compared to control app users. This consistent and clinically meaningful improvement underscores OTX-202’s therapeutic efficacy and potential utility as an adjunct to standard psychiatric care.

Suicide remains a formidable public health crisis in the United States, ranked among the top ten causes of death nationwide. It is notoriously the second leading cause of death among young populations aged 10–14 and 25–34, intensifying the urgency for innovations that effectively mitigate suicide risk. Rates have climbed by over 33% since 1999, reflecting a persistent and growing challenge for healthcare systems and societies alike.

Economic analyses estimate that suicide and suicide attempts cost the U.S. economy upwards of $500 billion annually, encompassing healthcare expenditures, lost productivity, and broader social impacts. Despite this burden, suicide prevention has lacked scalable and economically viable prescription-level interventions. OTX-202 represents a hopeful bridge toward closing this profound treatment gap.

Dr. Craig Bryan, PsyD, professor and director of the Suicide Prevention Program at Ohio State’s Department of Psychiatry and Behavioral Health, emphasized the app’s significance. He noted that the immediate months following hospital discharge are high-risk periods with limited access to trained therapists. OTX-202 offers a novel, scalable platform that could revolutionize suicide-specific intervention accessibility and continuity of care.

Co-first author Patricia Simon, PhD, from Yale School of Medicine, also highlighted the critical importance of addressing this vulnerable post-discharge window. She underscored that the app’s digital delivery model is particularly suited to meet the urgent demands for scalable mental health solutions that can be deployed widely and rapidly.

While OTX-202 is not intended to replace human clinicians, it serves as a powerful supplement that can extend evidence-based therapy beyond traditional settings. Its integration into treatment regimens could alleviate barriers related to therapist shortages, geographical limitations, and stigma associated with seeking mental health care.

The trial’s success was bolstered by funding support from Oui Therapeutics and a grant from the National Institute of Mental Health (NIMH). Importantly, the study’s authors caution that while results are promising, ongoing research is necessary to further validate the app’s long-term impact and scalability across broader clinical populations.

This study not only opens doors for innovative digital therapeutics in psychiatry but also sets a precedent for how technology can be harnessed to save lives in critical, high-risk mental health contexts. As healthcare systems grapple with demands for cost-effective and accessible interventions, OTX-202’s evidence-backed approach offers a beacon of hope for patients, clinicians, and policymakers striving to reduce suicide’s devastating toll.

Subject of Research: People

Article Title: A Digital Therapeutic Intervention for Inpatients with Elevated Suicide Risk

News Publication Date: 8-Aug-2025

Web References:

• JAMA Network Open Article
• Oui Therapeutics
• Ohio State University Wexner Medical Center
• Yale School of Medicine

References:

• National Institute of Mental Health grant number R42MH123357
• Economic cost estimate study: https://www.ajpmonline.org/article/S0749-3797(24)00081-3/fulltext

Image Credits: The Ohio State University Wexner Medical Center

Keywords: Suicide, Behavioral psychology, Clinical psychology, Neuropsychology